AR and neoplasm: In CRPC, the tumors recur and grow independently from of androgen serum levels and have been variously attributed to the upregulation of androgen receptor (AR) due to AR gene amplification, de novo AR upregulation by tumor cells, as well as gain-of-function mutations that affect AR stability or affinity for ligands [2].